Topics

FDA Accepts and Grants Priority Review for Epizyme’s Tazverik for Treatment of Relapsed or Refractory Follicular Lymphoma

10:14 EST 14 Feb 2020 | Speciality Pharma Journal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a fully integrated commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for the accelerated approval of TAZVERIK™ (tazemetostat) for patients with relapsed or refractory follicular lymphoma (FL) who have received at …

Original Article: FDA Accepts and Grants Priority Review for Epizyme’s Tazverik for Treatment of Relapsed or Refractory Follicular Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts and Grants Priority Review for Epizyme’s Tazverik for Treatment of Relapsed or Refractory Follicular Lymphoma"

Quick Search

Relevant Topic

Epigenetics
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...